← Back to Search

Gastrojejunostomy Techniques for Gastric Outlet Obstruction

N/A
Recruiting
Led By Ji Young Bang, MD MPH
Research Sponsored by Orlando Health, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Presence of gastric outlet obstruction on any imaging or endoscopy from known or suspected malignancy
Must not have
Use of anticoagulants that cannot be discontinued for the procedure
Age < 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial compares the outcomes of two treatments for a cancer that is blocking the stomach from emptying into the small intestine.

Who is the study for?
This trial is for adults over 18 with gastric outlet obstruction due to cancer, who can only consume liquids. It's not for those under 18, pregnant women, or patients on anticoagulants that can't be stopped.
What is being tested?
The study compares two procedures in patients with malignant gastric outlet obstruction: EUS-guided gastrojejunostomy (a less invasive endoscopic procedure) and traditional surgical gastrojejunostomy.
What are the potential side effects?
Possible side effects include pain at the procedure site, infection risk, bleeding complications especially if previous anticoagulant use isn't properly managed, and potential anesthesia-related issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have a blockage in my stomach due to cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am on blood thinners that cannot be stopped for a procedure.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite end point of inability to tolerate a solid diet (defined as gastric outlet obstruction scoring system score <2) or requiring endoscopic or surgical intervention or supplemental nutrition or procedure-related adverse events.
Secondary study objectives
Gastric Outlet Obstruction Scoring System (GOOSS) score of ≥ 2 at 1-month post-procedure, without the need for repeat intervention or supplemental nutrition such as the use of enteric feeding tubes or total parenteral nutrition (TPN).
Gastric Outlet Obstruction Scoring System (GOOSS) score of ≥ 2 at 6-month post-procedure, without the need for repeat intervention or supplemental nutrition such as the use of enteric feeding tubes or total parenteral nutrition (TPN).
Length of survival
+12 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: EUS-guided gastrojejunostomyActive Control1 Intervention
EUS-guided gastrojejunostomy is performed using a lumen-apposing metal stent
Group II: Surgical gastrojejunostomyActive Control1 Intervention
A surgical gastrojejunostomy will be created via laparoscopic or open technique, as clinically appropriate.

Find a Location

Who is running the clinical trial?

The Medicity Hospital, MedantaUNKNOWN
University of Hamburg-EppendorfOTHER
36 Previous Clinical Trials
354,164 Total Patients Enrolled
Asian Institute of Gastroenterology HospitalsUNKNOWN

Media Library

EUS-guided gastrojejunostomy Clinical Trial Eligibility Overview. Trial Name: NCT05548114 — N/A
Gastric Outlet Obstruction Research Study Groups: EUS-guided gastrojejunostomy, Surgical gastrojejunostomy
Gastric Outlet Obstruction Clinical Trial 2023: EUS-guided gastrojejunostomy Highlights & Side Effects. Trial Name: NCT05548114 — N/A
EUS-guided gastrojejunostomy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05548114 — N/A
~22 spots leftby Dec 2025